Team 1 publications

Full list of publications: Pubmed link

 5-key translationnal publications from Team #1

1. Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling.
   PNAS 2025.

2. Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension.
   Eur Respir J. 2024.

3. Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension.
   Circulation. 2023.

4. Disrupted BMP-9 signaling impairs pulmonary vascular integrity in hepatopulmonary syndrome.
   Am J Respir Crit Care Med. 2024.

5. Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10.
   Cardiovasc Res. 2022.

 5-key clinical publications from Team #1

1. Sotatercept for pulmonary arterial hypertension within the first year after diagnosis.
   N Engl J Med. 2025. (HYPERION Trial)

2. Sotatercept in patients with pulmonary arterial hypertension at high risk for death.
   N Engl J Med. 2025. (ZENITH Trial)

3. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension.
   N Engl J Med. 2023. (STELLAR Trial)

4. Sotatercept for the treatment of pulmonary arterial hypertension.
   N Engl J Med. 2021. (PULSAR Trial)

5. Cardiopulmonary hemodynamic determinants of long-term survival in sickle cell disease: Insights from the ETENDARD Study.
   Am J Respir Crit Care Med. 2025.